Pharmaceuticals, Biotechnology and Life Sciences
Syros’s SY-1425 plus Azacitidine testing data showed 62% composite complete response rate, with 82% of patients achieving or maintaining transfusion…
Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”
BerGenBio ASA has been dosed the first patient with bemcentinib, in an investigator-initiated phase II trial, sponsored by GWT-TUD GmbH, a specialist cancer clinical research institution associated with the University of Dresden, Germany.